Nylexa (NM002)

Antibiotic resistance is a major health threat worldwide. An existing problem only set to worsen. Addressing this crisis of modern medicine is a now a global imperative.

Nylexa® is one potential solution to the worsening antibiotic resistance crisis and a strategy that could be introduced into clinical practice within a much shorter timescale than any new antibiotic(s) developed from first principle. In vitro and in vivo data generated thus far have demonstrated Nylexa's efficacy in a number of infection models, supported by Lynovex® clinical data.

Derived from NovaBiotics cysteamine platform Nylexa® is an antibiotic potentiator/resistance breaking agent being developed as an adjunct (intravenous and oral) to a number of antibiotic classes; extending their utility and scope against drug resistant, even MDR and XDR bacterial infections. Put simply, when used alongside certain existing antibiotics against drug resistant bacterial pathogens, Nylexa® allows that antibiotic to work again or work better than it did before, both in terms of potency (dose required) and spectrum of activity.


We must increase the supply of new antimicrobials effective against drug-resistant drugs